Mighty Therapeutics Initiates IND-Enabling Studies of MYTX-255: a Mitochondrial-Targeted Therapeutic Candidate

CHARLOTTE, N.C. – September 1, 2026 – In August 2026, Edward C. Brown III, MD, was elected to join the ranks of the American Shoulder and Elbow Surgeons (ASES) as a General Member. General membership in ASES is a privilege and an honor only awarded to young orthopaedic s...

Six events held across four counties will feature national guest speakers, caregiver panels, and a virtual advance care planning workshop

BLUFFTON, S.C.-- Aug. 18, 2026 -- “South Carolina’s 2026-2027 budget sends a strong message: The future of health care is moving into the home. While much of the conversation has focused on the dollars invested, the bigger story is the state’s continued commitment to hel...

NEEDHAM, Mass. — August 11, 2026 — Mighty Therapeutics (the “Company” or “Mighty”), a commercial-stage biotechnology company pioneering a new class of medicines that directly target mitochondrial dysfunction in rare and age-related diseases, today announced that a joint ...

Company Recognized for 167% Three-Year Revenue Growth, Earning a Place Among the Nation’s Most Successful Independent Businesses

NEW ORLEANS — Aug. 10, 2026 — The Offshore Marine Service Association (OMSA) is responding to the Trump administration's decision to extend the current Jones Act waiver despite clear evidence it has failed to lower fuel prices while continuing to undermine American marit...

- FDA confirmed the resubmission is a complete, Class II response to the Aug. 27, 2025 CRL.

Global Real Estate Veteran Angela Healy says increasing housing supply remains critical to affordability and workforce growth

Restated Marine Safety Mission and New Civilian Secretary of the Coast Guard proposed as solutions